Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. (2024). Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer. Available from https://gco.iarc.who.int/today

World Health Organization. (2020). Cervical cancer. Retrieved from https://www.who.int/health-topics/cervical-cancer#tab=tab_1

Yang-Chun F, Zhen-Zhen C, Yan-Chun H, Xiu-Min M. Association between PD-L1 and HPV status and the prognostic value for HPV treatment in premalignant cervical lesion patients. Med (Baltim). 2017;96:1–12.

Article  Google Scholar 

Heeren AM, Punt S, Bleeker MC, Gaarenstroom KN, VanderVelden J, Kenter GG, et al. Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix. Mod Pathol. 2016;29:753–63.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Baş Y, Şenel E. A holistic evaluation of articles on PD-1 and PD-L1 published between 1975 and 2017: A bibliometric analysis. Cancer Inform. 2019;18:1–17.

Article  Google Scholar 

Enwere EK, Kornaga EN, Dean M, Koban I, Morris DG, Doll CM. Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer. Mod Pathol. 2017;30(4):577–86.

Article  CAS  PubMed  Google Scholar 

Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 Immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Pardoll DM. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mezache L, Paniccia B, Nyinawabera A, Nuovo GJ. Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers. Mod Pathol. 2015;28:1594–602.

Article  CAS  PubMed  Google Scholar 

Heeren AM, Rotman J, Bosse T, Gaarenstroom KN, Creutzberg CL, van der Burg SH, de Gruijl TD. Efficacy of PD-1 Blockade in HPV-related cervical cancer. J Clin Oncol. 2016;34(15suppl):3057–3057.

Google Scholar 

Frenel JS, Le Tourneau C, O’Neil B, Ott PA, Piha-Paul SA, Gomez-Roca C, Leary A. Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: results from the phase Ib KEYNOTE-028 trial. J Clin Oncol. 2017;35(36):4035–41.

Article  CAS  PubMed  Google Scholar 

Schellens JHM, et al. Pembrolizumab for previously treated advanced cervical squamous cell cancer: preliminary results from the phase 2 KEYNOTE-158 study. J Clin Oncol. 2017;35:5514–5514.

Article  Google Scholar 

Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother. 2017;66:551–64.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chaudhary N, Raju K, Sheela SR, Sakalecha AK, Manjunath GN. Programmed death ligand (PD-L1) expression in invasive squamous cell carcinoma of the uterine cervix: A cross-sectional observational study. Cancer Res Statutory Treatments. 2022;5:461–7.

Article  Google Scholar 

Grochot RM, et al. Expression of PD-L1 in cervical carcinoma and its impact on survival associated with T-cell infiltration and FoxP3 expression. Cancer Manage Res. 2019;11:4597–605. https://doi.org/10.2147/CMAR.S194597.

Article  CAS  Google Scholar 

Franceschi C et al. (2017). Inflammaging and multi-morbidity: the role of immune senescence. Nat Rev Immunol.

Fischer RJ, et al. The impact of reproductive factors on immune responses and cancer risk. Cancer Immunol Res. 2021;9(1):1–10.

Google Scholar 

Vignali DA et al. (2017). How the immune system influences cancer. Nat Rev Immunol.

Chen DS, Mellman I. (2019). Elements of cancer immunity and the cancer-immune set point. Nature.

de Berrington A, et al. Socioeconomic status and cancer risk. Cancer Epidemiol Biomarkers Prev. 2015;24(3):362–8.

Google Scholar 

Lloyd-Price J et al. (2016). Striking changes in gut Microbiome during diet and the interplay between diet and the immune system. Nature.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–55.

Article  CAS  PubMed  Google Scholar 

Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291(20):2441–7. https://doi.org/10.1001/jama.291.20.2441.

Article  CAS  PubMed  Google Scholar 

Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for immune checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19(3):133–50. https://doi.org/10.1038/s41568-019-0116-x.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chung HC, Ros W, Delord JP, Perets R, Italiano A, Shapira-Frommer R, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2019;37(17):1470–8. https://doi.org/10.1200/JCO.18.01265.

Article  CAS  PubMed  Google Scholar 

Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, Olivera H, de Samouëlian M, Castonguay V, Arkhipov V, Tekin A, Li C, Keefe K, S. M., Lorusso D. On behalf of the KEYNOTE-826 Investigators. (2023). First-line pembrolizumab plus chemotherapy versus placebo plus chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826 [Journal Article]. J Clin Oncol, 41(36), 5505–11. https://doi.org/10.1200/JCO.23.00914

Colombo N, Dubot C, Lorusso D, Caceres MV, Hasegawa K, Shapira-Frommer R, et al. Pembrolizumab for persistent, recurrent, or metastatic cervical cancer. N Engl J Med. 2021;385(20):1856–67. https://doi.org/10.1056/NEJMoa2112435.

Article  CAS  PubMed  Google Scholar 

College of American Pathologists. PD-L1 immunohistochemistry testing in solid tumors: guidelines and recommendations for pathologists. Arch Pathol Lab Med. 2020;144(6):766–84.

Google Scholar 

Sarfati D, Koczwara B, Jackson C. The impact of comorbidity on cancer and its treatment. Cancer J Clin. 2016;66(4):337–50. https://doi.org/10.3322/caac.21342.

Article  Google Scholar